Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BMRN
BMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMRN News
Emerging Trends in Rare Disease Drug Development
3d ago
CNBC
BioMarin Q1 Earnings: Amicus Acquisition Fuels Growth
5d ago
seekingalpha
BioMarin Reports Significant Revenue Growth in Q1 2026
5d ago
PRnewswire
VOXZOGO Shows Positive Long-Term Effects on Children's Bone Health
May 02 2026
PRnewswire
New Research on VOXZOGO in Children with Achondroplasia
May 02 2026
Newsfilter
BioMarin Pharmaceutical Q1 Earnings Announcement Scheduled
May 01 2026
seekingalpha
BioMarin Acquires Amicus for $4.8 Billion to Enhance Rare Disease Portfolio
Apr 27 2026
PRnewswire
Intellia's Gene Editing Therapy Trial Achieves Success
Apr 27 2026
CNBC
BioMarin to Host Q1 2026 Financial Results Call on May 4
Apr 27 2026
PRnewswire
BioMarin to Host Q1 2026 Financial Results Call on May 4
Apr 27 2026
Newsfilter
BioMarin Appoints New Board Chair Ian Clark
Apr 22 2026
NASDAQ.COM
BioMarin Appoints New Chair of the Board
Apr 21 2026
PRnewswire
BioMarin Elects Ian T. Clark as Board Chair
Apr 21 2026
Newsfilter
CNBC Launches Advocacy Platform for Rare Diseases
Mar 20 2026
CNBC
BioMarin Discontinues Voxzogo Trials Amid Safety Concerns
Mar 16 2026
seekingalpha
VOXZOGO Treatment Shows Significant Improvements in Children's Skeletal Growth
Mar 12 2026
PRnewswire
Show More News
